NCT07201844

Brief Summary

The goal of this clinical trial is to investigate the effect of allowing patients to choose between two internet-based cognitive behavioral treatments (ICBT) for generalized anxiety disorder (GAD). The goal is also to examine psychologists' ability to predict which of the two treatments the patient will benefit most from. The main questions it aims to answer are:

  • Do patients who are randomized to choose their treatment improve more in their GAD symptoms compared to patients who are randomly assigned to a treatment?
  • Does allowing patients to choose their treatment increase treatment adherence, compared to being randomly assigned to a treatment?
  • Does allowing patients to choose their treatment increase treatment satisfaction and credibility, compared to being randomly assigned to a treatment?
  • Does allowing patients to choose their treatment increase patients' sense of agency related to the treatment process, compared to being randomly assigned to a treatment?
  • Do patients who receive a treatment that matches the psychologist's prediction of which treatment would fit the patient best show better treatment outcomes (primarily reduction in GAD symptoms over time, but also secondary outcomes such as satisfaction), compared to patients who receive a treatment that does not match the psychologist's prediction? Participants included in the trial will be randomized to one of two conditions: 1) read short descriptions of the two treatment programs and based on that choose the preferred treatment, 2) randomly being allocated to one of the two treatments. The two internet-based treatment programs which the patients can choose between or be randomly allocated to are: 1) Intolerance of uncertainty-based ICBT and 2) Metacognition-based ICBT. Both programs consist of 8 treatment modules and run for 10 weeks. Patients in both conditions receive continuous support by a psychologist through a built-in message function on the treatment platform. The patient will receive feedback from the psychologist on their assignments and exercises and the psychologist will respond to the participants' messages.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
440

participants targeted

Target at P75+ for not_applicable

Timeline
29mo left

Started Aug 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress23%
Aug 2025Aug 2028

Study Start

First participant enrolled

August 26, 2025

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

September 16, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

October 1, 2025

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2028

Last Updated

October 1, 2025

Status Verified

September 1, 2025

Enrollment Period

2 years

First QC Date

September 16, 2025

Last Update Submit

September 23, 2025

Conditions

Keywords

Internet interventionsDigital mental health servicescognitive behaviour therapypatient preferencespsychiatry

Outcome Measures

Primary Outcomes (1)

  • Change in Generalized Anxiety Disorder - score (GAD-7)

    Measures generalized anxiety symptoms. 7 items. Scores range from 0-21 with higher scores indicating more generalized anxiety

    Measured weakly from treatment start (pre-treatment) to 10 weeks after treatment start (post-treatment).

Secondary Outcomes (7)

  • Therapeutic Agency Inventory (adapted to the clinic)

    4 weeks after treatment start.

  • Penn-State Worry Questionnaire (PSWQ)

    At start of treatment (pre-treatment) and at 10 weeks after treatment start (post-treatment).

  • Client satisfaction questionnaire (adapted to the clinic)

    10 weeks after treatment start (post-treatment).

  • Treatment Credibility Questionnaire (adapted to the clinic)

    2 weeks after treatment start.

  • Montomery-Asberg Depression Rating Scale - Self-rated (MADRS-S)

    Measured weakly from treatment start (pre-treatment) to 10 weeks after treatment start (post-treatment).

  • +2 more secondary outcomes

Study Arms (2)

Treatment choice

EXPERIMENTAL

Patients have been randomized to getting to read about and then choose one of the two treatments

Behavioral: Metacognitive Internet delivered Cognitive Behavior TherapyBehavioral: Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy

Random assignment to treatment

EXPERIMENTAL

Patients have been directly randomized into one of the two treatments

Behavioral: Metacognitive Internet delivered Cognitive Behavior TherapyBehavioral: Intolerance of uncertainty based Internet delivered Cognitive Behavior Therapy

Interventions

Specialist Guided Internet delivered Cognitive Behavior Therapy based on the metacognitive model of excessive worry

Random assignment to treatmentTreatment choice

Specialist Guided Internet delivered Cognitive Behavior Therapy based on the Intolerance of uncertainty model of excessive worry

Random assignment to treatmentTreatment choice

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years or older.
  • Meet diagnostic criteria for GAD according to DSM-5, as assessed by a psychologist on a video-call.
  • Self-rated score ≥ 7 on GAD-7.
  • Can read and speak Swedish fluently.
  • Have access to a smartphone, tablet, or computer and a Swedish BankID which allows access to the video-calls and treatment platform.
  • Have the time and possibility to participate in the 10 week treatment.
  • Consents to participate.

You may not qualify if:

  • Patients that are judged to be in greater need of another psychiatric treatment for another psychiatric diagnosis (for example severe depression) and/or is judged to have a high risk of suicide.
  • Current drug or alcohol abuse.
  • Current severe somatic health concern or social vulnerability if this is judged to be too great an obstacle for the patient to carry out the treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Internet Psychiatry Clinic, Psychiatry Southwest, SLSO, Region Stockholm, Stockholm, Huddinge 14135

Stockholm, Sverige, 14132, Sweden

RECRUITING

MeSH Terms

Conditions

Generalized Anxiety DisorderPatient Preference

Condition Hierarchy (Ancestors)

Anxiety DisordersMental DisordersPatient SatisfactionTreatment Adherence and ComplianceHealth BehaviorBehavior

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Participants who do not get to choose treatment are not aware that they could have been assigned to do so.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Researcher

Study Record Dates

First Submitted

September 16, 2025

First Posted

October 1, 2025

Study Start

August 26, 2025

Primary Completion (Estimated)

August 31, 2027

Study Completion (Estimated)

August 31, 2028

Last Updated

October 1, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

All IPD will be confidential patient records and as such are not shareable.

Locations